These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21111635)

  • 1. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke.
    Ikeda T; Maruyama K; Ito N; Utagawa A; Nagane M; Shiokawa Y
    J Stroke Cerebrovasc Dis; 2012 Jul; 21(5):386-90. PubMed ID: 21111635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum pentosidine in branch atheromatous disease among small vessels occlusion.
    Ikeda T; Maruyama K; Ito N; Utagawa A; Shimada A; Shiokawa Y; Kurita H
    J Neurosurg Sci; 2019 Aug; 63(4):388-393. PubMed ID: 26899301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.
    Koyama Y; Takeishi Y; Arimoto T; Niizeki T; Shishido T; Takahashi H; Nozaki N; Hirono O; Tsunoda Y; Nitobe J; Watanabe T; Kubota I
    J Card Fail; 2007 Apr; 13(3):199-206. PubMed ID: 17448417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M; Franke S; Stein G; Wolf G;
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease.
    Kerkeni M; Weiss IS; Jaisson S; Dandana A; Addad F; Gillery P; Hammami M
    Thromb Res; 2014 Sep; 134(3):633-8. PubMed ID: 25065554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
    Yoshida N; Okumura K; Aso Y
    Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum pentosidine with arterial stiffness in hemodialysis patients.
    Zhou Y; Yu Z; Jia H; Sun F; Ma L; Guo R; Peng L; Cui T
    Artif Organs; 2010 Mar; 34(3):193-9. PubMed ID: 20447043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
    Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
    J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
    Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
    J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Müller UA; Stein G
    Eur J Med Res; 2004 Aug; 9(8):391-9. PubMed ID: 15337629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
    Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
    Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis.
    Kitauchi T; Yoshida K; Yoneda T; Saka T; Yoshikawa M; Ozono S; Hirao Y
    Clin Exp Nephrol; 2004 Mar; 8(1):48-53. PubMed ID: 15067516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosidine and its deposition in renal tissue in renal transplantation.
    Yoshida K; Yoneda T; Fujimoto K; Hirao Y; Konishi N
    Transplant Proc; 2005 Dec; 37(10):4266-72. PubMed ID: 16387094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are advanced glycation end products cardiovascular risk factors in patients with CRF?
    Stein G; Busch M; Müller A; Wendt T; Franke C; Niwa T; Franke S
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S52-6. PubMed ID: 12612953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.